RADX — Radiopharm Theranostics Ltd
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Wall Street Analyst Consensus
Ratings, 12-month price target and EPS forecasts from the Nasdaq public analyst feed. · Fetched 2026-11-19
| Fiscal year end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Jun 2027 | -3.23 | — | -3.23 | -3.23 | 1 | — |
Forward P/E uses the fetch-time price divided by consensus EPS (quarter annualised ×4). Revision score = (upgrades − downgrades) / estimates, from Nasdaq 4-week counts. Source: Nasdaq analyst data
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 7 SEC-registered investment managers reported holding RADX (Radiopharm Theranostics Ltd) in their latest 13F filings, with a combined reported value of $1.00M across 621.69K shares. That is -8.5% by share count (-10.49K shares) versus the previous quarter, while reported value moved -64.6%. Ownership is concentrated: the five largest holders account for 99.8% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 2 opened new positions, 1 added to existing stakes, 2 trimmed, 2 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of Radiopharm Theranostics Ltd (RADX) include SILVERARC CAPITAL MANAGEMENT, LLC, ARMISTICE CAPITAL, LLC, Stonepine Capital Management, LLC, ranked by reported 13F value among the 14 institutional holders on this page.
RADX is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 7 | 621.69K | $1.00M | -8.5% |
| Q2 2026 | 7 | 51.13M | $1.19M | +0.0% |
| Q1 2026 | 7 | 51.31M | $2.06M | -0.4% |
| Q4 2025 | 11 | 51.54M | $3.67M | -1.3% |
| Q3 2025 | 4 | 312.51K | $1.73M | +2.8% |
| Q2 2025 | 5 | 339.69K | $1.58M | -8.4% |
| Q1 2025 | 3 | 342.92K | $1.65M | -21.1% |
| Q4 2024 | 4 | 435.80K | $1.94M | — |
Over the 8 quarters shown, institutional share counts increased 43% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q1 2025 (-21.1%).
Top Institutional Holders (Q3 2026) — 7 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 450.00K | $729.00K | 0.01% | New | |
| 58.15K | $94.21K | 0.00% | New | |
| 50.00K | $81.00K | 0.00% | Add | |
| 39.98K | $64.76K | 0.00% | Hold | |
| 22.48K | $33.95K | 0.00% | Reduce | |
| 883 | $1.43K | 0.00% | Reduce | |
| 195 | $315 | 0.00% | Hold |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 7 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 51.00M | $670.50K | 0.44% | Hold | |
| 62.19K | $253.73K | 0.00% | Add | |
| 40.14K | $168.18K | 0.01% | Hold | |
| 20.00K | $83.80K | 0.00% | Add | |
| 1.51K | $6.31K | 0.00% | Reduce | |
| 1.31K | $5.49K | 0.00% | New | |
| 195 | $817 | 0.00% | Add |
Q1 2026 — 7 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 187.41K | $805.85K | 0.10% | Hold | |
| 51.00M | $738.98K | 0.44% | Hold | |
| 61.37K | $264.51K | 0.00% | Reduce | |
| 40.14K | $172.59K | 0.01% | Reduce | |
| 16.00K | $68.80K | 0.00% | Hold | |
| 3.00K | $12.90K | 0.00% | Reduce | |
| 121 | $519 | 0.00% | Add |
Q4 2025 — 11 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 191.62K | $1.01M | 0.00% | New | |
| 187.41K | $978.26K | 0.15% | Hold | |
| 51.00M | $850.85K | 0.66% | New | |
| 90.91K | $474.55K | 0.03% | Hold | |
| 16.00K | $83.52K | 0.00% | Hold | |
| 14.59K | $76.00K | 0.00% | New | |
| 14.47K | $75.53K | 0.00% | New | |
| 14.28K | $74.53K | 0.00% | Reduce | |
| 10.29K | $53.69K | 0.00% | New | |
| 10 | $52 | 0.00% | New | |
| 6 | $31 | 0.00% | New |
Q3 2025 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 187.41K | $1.03M | 0.15% | Hold | |
| 90.91K | $501.82K | 0.04% | Hold | |
| 18.19K | $100.41K | 0.00% | Add | |
| 16.00K | $88.32K | 0.00% | Add |
Q2 2025 — 5 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 187.41K | $869.56K | 0.18% | Hold | |
| 90.91K | $421.82K | 0.04% | Hold | |
| 35.63K | $166.06K | 0.03% | Reduce | |
| 17.74K | $82.31K | 0.00% | New | |
| 8.00K | $37.12K | 0.00% | New |
New Positions (Q3 2026)
- ARMISTICE CAPITAL, LLC 450.00K sh · $729.00K
- Marex Group Ltd 58.15K sh · $94.21K
Fully Exited (vs previous quarter)
- Stonepine Capital Management, LLC sold 51.00M sh · $670.50K
- Integrated Wealth Concepts LLC sold 1.31K sh · $5.49K
Fund Position History — shares by quarter (top 14 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 450.00K | — | — | — | — | — | — | — |
| Marex Group Ltd | 58.15K | — | — | 10.29K | — | — | — | — |
| PNC Financial Services | 50.00K | 20.00K | 16.00K | 16.00K | 16.00K | 8.00K | — | — |
| Regal Partners Ltd | 39.98K | 40.14K | 40.14K | 90.91K | 90.91K | 90.91K | 90.91K | 90.91K |
| HSBC HOLDINGS PLC | 22.48K | 62.19K | 61.37K | 191.62K | — | — | — | — |
| UBS Group AG | 883 | 1.51K | 3.00K | 14.28K | 18.19K | 17.74K | — | 1.32K |
| RHUMBLINE ADVISERS | 195 | 195 | 121 | 6 | — | — | — | — |
| SILVERARC CAPITAL MANAGEMENT, LLC | — | — | 187.41K | 187.41K | 187.41K | 187.41K | 187.41K | 187.41K |
| Stonepine Capital Management, LLC | — | 51.00M | 51.00M | 51.00M | — | — | — | — |
| Affinity Asset Advisors, LLC | — | — | — | — | — | 35.63K | 64.60K | 156.17K |
| Virtu Financial LLC | — | — | — | 14.59K | — | — | — | — |
| JANE STREET GROUP, LLC | — | — | — | 14.47K | — | — | — | — |
| Integrated Wealth Concepts LLC | — | 1.31K | — | — | — | — | — | — |
| Strategic Wealth Partners, Ltd. | — | — | — | 10 | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold RADX?
As of 2026-Q3, 7 institutional funds reported holding RADX (Radiopharm Theranostics Ltd) in SEC 13F filings, with a combined reported value of $1.00M.
How many shares of RADX do institutions own?
13F filers reported 621.69K shares of RADX, worth $1.00M in aggregate at the end of 2026-Q3.
Is institutional ownership of RADX rising or falling?
Share counts moved -8.5% versus the prior quarter — distribution.
Who are the top institutional holders of RADX?
The largest 13F holders are SILVERARC CAPITAL MANAGEMENT, LLC, ARMISTICE CAPITAL, LLC, Stonepine Capital Management, LLC, Affinity Asset Advisors, LLC, Marex Group Ltd; the top 25 are ranked at the top of this page.
Who are the major shareholders of Radiopharm Theranostics Ltd?
The major shareholders of Radiopharm Theranostics Ltd (RADX) by reported 13F value are SILVERARC CAPITAL MANAGEMENT, LLC, ARMISTICE CAPITAL, LLC, Stonepine Capital Management, LLC, Affinity Asset Advisors, LLC, Marex Group Ltd, among 14 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.